CoChat

Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis

Open access

The DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Although meta-analyses have shown that placebo responses are large in Major Depressive Disorder (MDD) trials; the placebo response of devices such as repetitive transcranial magnetic stimulation (rTMS) has not been systematically assessed. We proposed to assess placebo responses in two categories of MDD trials: pharmacological (antidepressant drugs) and non-pharmacological (device- rTMS) trials. METHODOLOGY/PRINCIPAL FINDINGS: We performed a systematic review and meta-analysis of the literature from April 2002 to April 2008, searching MEDLINE, Cochrane, Scielo and CRISP electronic databases and reference lists from retrieved studies and conference abstracts. We used the keywords placebo and depression and escitalopram for pharmacological studies; and transcranial magnetic stimulation and depression and sham for non-pharmacological studies. All randomized, double-blinded, placebo-controlled, parallel articles on major depressive disorder were included. Forty-one studies met our inclusion criteria - 29 in the rTMS arm and 12 in the escitalopram arm. We extracted the mean and standard values of depression scores in the placebo group of each study. Then, we calculated the pooled effect size for escitalopram and rTMS arm separately, using Cohen's d as the measure of effect size. We found that placebo response are large for both escitalopram (Cohen's d - random-effects model - 1.48; 95%C.I. 1.26 to 1.6) and rTMS studies (0.82; 95%C.I. 0.63 to 1). Exploratory analyses show that sham response is associated with refractoriness and with the use of rTMS as an add-on therapy, but not with age, gender and sham method utilized. CONCLUSIONS/SIGNIFICANCE: We confirmed that placebo response in MDD is large regardless of the intervention and is associated with depression refractoriness and treatment combination (add-on rTMS studies). The magnitude of the placebo response seems to be related with study population and study design rather than the intervention itself.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0004824

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 QUOROM flow chart used to identify studies for detailed analysis.
Figure 1 QUOROM flow chart used to identify studies for detailed analysis.CC BY · PubMed Central
Figure 2 Forest plots showing placebo response in control groups of escitalopram (A) and rTMS (B) studies. Forest plots show effect sizes from the random effects model. A negative effect indicates that endpoint depression scores in control groups are higher than baseline scores. Effect sizes are Cohen's d (standardized mean difference), error bars represent the 95% confidence interval.
Figure 2 Forest plots showing placebo response in control groups of escitalopram (A) and rTMS (B) studies. Forest plots show effect sizes from the random effects model. A negative effect indicates that endpoint depression scores in control groups are higher than baseline scores. Effect sizes are Cohen's d (standardized mean difference), error bars represent the 95% confidence interval.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Cited by

See all 173

Metadata

Authors
Brunoni, A. R., Lopes, M., Kaptchuk, T. J., & Fregni, F.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • Harvard University (US)
Corresponding author
Fregni, Felipe
Venue
PLoS ONE
Published
2009-03-18
Volume
4
Issue
3
Pages
e4824
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2057880023
Cited by
173
References
74
Citations by year
2026: 5 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 8 · 2019: 9 · 2018: 12 · 2017: 6 · 2016: 6 · 2015: 15 · 2014: 10 · 2013: 16 · 2012: 13
FWCI
1.18
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
National Center for Complementary and Integrative Health (K24AT004095)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
placebo response, major depressive disorder, repetitive transcranial magnetic stimulation, escitalopram, antidepressants, treatment-resistant depression, adjunctive therapy
MeSH terms
Major Depressive Disorder, Double-Blind Method, Humans, Placebos, Citalopram, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1371/journal.pone.0004824
The paper
Brunoni, A. R., Lopes, M., Kaptchuk, T. J., & Fregni, F. (2009). Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0004824

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.